The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
The OncoAlert Newsletter is now out for June 23-29, 2023
Researchers say social media companies have ‘substantial power’ to reduce young people’s exposure to smoking and vaping
On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer.
During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.
Stop asking the wrong question. Whether they smoked or never had a puff, all people with a lung cancer diagnosis deserve care and compassion.
USC’s Berislav Zlokovic has faced questions about the integrity of his research. Since a whistleblower report last year, several papers have been retracted and a…
Low-value care is defined “as the use of a health service for which the harms or costs outweigh the benefits”. In other words, if a…
We study the medium-run effect of Sure Start on academic outcomes, finding large benefits, particularly for children from disadvantaged backgrounds.
Prescription drug costs are a challenge for patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, aiming to provide transp
Chronic musculoskeletal pain remains a huge challenge for clinicians and researchers. Exercise interventions are the cornerstone of management for musculoskeletal pain conditions,1 with the benefits…
PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with…